HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Research Center for Zoonosis Control >
Peer-reviewed Journal Articles, etc >

Discovery of an antibody for pan-ebolavirus therapy

Creative Commons License

Files in This Item:
srep20514-s1.pdfSupplementary Information225.94 kBPDFView/Open
srep20514.pdf1.04 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Discovery of an antibody for pan-ebolavirus therapy
Authors: Furuyama, Wakako Browse this author
Marzi, Andrea Browse this author
Nanbo, Asuka Browse this author →KAKEN DB
Haddock, Elaine Browse this author
Maruyama, Junki Browse this author
Miyamoto, Hiroko Browse this author
Igarashi, Manabu Browse this author →KAKEN DB
Yoshida, Reiko Browse this author
Noyori, Osamu Browse this author
Feldmann, Heinz Browse this author
Takada, Ayato Browse this author →KAKEN DB
Issue Date: 10-Feb-2016
Publisher: Nature Publishing Group
Journal Title: Scientific Reports
Volume: 6
Start Page: 20514
Publisher DOI: 10.1038/srep20514
Abstract: During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.
Type: article
Appears in Collections:人獣共通感染症リサーチセンター (Research Center for Zoonosis Control) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 高田 礼人

Export metadata:

OAI-PMH ( junii2 , jpcoar )


Feedback - Hokkaido University